



Sandwich-Elisa of Several A β -Forms with Biotinylated
Clone 8F5 Coated Clone 6G1

coated anti-A β clone 6G1 ---> A β -Forms ---> biotinylated clone
8F5 ---> Streptavidin-POD ---> development



	A β (1-42) oligomer	HFIP monomer A β (1-42)	NH ₄ OH monomer A β (1-42)	HFIP monomer A β (1-40)
BOTTOM	-0.001218	0.004304	0.006727	0.004288
TOP	0.9926	1.002	0.9292	0.1116
LOCEC50	1.958	2.745	3.003	2.825
HILLSLOPE	1.215	1.270	1.204	1.375
EC50	90.74	555.8	1007	667.8

FIG.1



1. Marker
2. Fibril preparation control
3. Fibril preparation ; + mMAb 6E10 ; 20h 37°C ; supernatant
4. Fibril preparation ; + mMAb 6E10 ; 20h 37°C ; pellet
5. Fibril preparation ; + mMAb 4G8 ; 20h 37°C ; supernatant
6. Fibril preparation ; + mMAb 4G8 ; 20h 37°C ; pellet
7. Fibril preparation ; + mMAb 8F5 ; 20h 37°C ; supernatant
8. Fibril preparation ; + mMAb 8F5 ; 20h 37°C ; pellet

FIG.2

3/14






FIG.3

4/14



*** $P < 0.001$ vs. 50%
○ $P < 0.05$; ○○ $P < 0.01$
post hoc t-test vs. PBS after $P < 0.001$ in ANOVA

FIG.4

5/14

VH 8F5

GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGCCC
TGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTTCAGTAGCTATGGCATGTCT
TGGGTTCCGCCAGACTCCAGACAAGAGGCTGGAATTGGTCGCAAGCATCAATA
GTAATGGTGGTAGCACCTATTATCCAGACAGTGTGAAGGGCCGATTACCAT
CTCCAGAGACAATGCCAAGAACACCCTGTACCTGCAAAATGAGCAGTCTGAAG
TCTGAGGACACAGCCATGTATTACTGTGCAAGTGGTGACTACTGGGGCCAAG
GCTCCACTCTCACAGTCTCCTCA (SEQ ID NO:1)

FIG.5A

VL 8F5

GATGTTGTGATGACCCAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCA
AGCCTCCATCTCTTGCAGATCTAGTCAGAGCCTTGTATATAGTAATGGAGACA
CCTATTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCAAAGCTCCTGATC
TACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTG
GATCAGGGACAGATTTCACTCAAGATCAGCAGAGTGGAGGCTGAGGATCT
GGGAGTTTATTTCTGCTCTCAAAGTACACATGTTTCTTGGACGTTCCGGTGGAG
GCACCAAGCTAGAAATCAAACGG (SEQ ID NO:2)

FIG.5B

6/14

VH 8F5

EVQLVESGGGLVQPGGSLKLSCAASGFTFSSYGMSWVRQTPDKRLELVASINSN
GGSTYYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCASGDYWGQGST
LTVSS (SEQ ID NO:3)

CDR1 (VH) = SYGMS (SEQ ID NO:5)
CDR2 (VH) = SINSNGGSTYYPDSVKG (SEQ ID NO:6)
CDR3 (VH) = SGDY (SEQ ID NO:7)

FIG.6A

VL 8F5

DVVMTQTPLSLPVSLGDQASISCRSSQSLVYSNGDITYLHWYLQKPGQSPKLLIYK
VSNRFSGVDPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTKLE
IKR (SEQ ID NO:4)

CDR1(VL) = RSSQSLVYSNGDITYLH (SEQ ID NO:8)
CDR2(VL) = KVSNRFS (SEQ ID NO:9)
CDR3(VL) = SQSTHVPWT (SEQ ID NO:10)

FIG.6B

7/14




FIG.7A

8/14




FIG.7B

9/14





FIG.7C


Binding to amyloid plaques in Tg2576



Antibody

FIG.7D


Binding to amyloid plaques in AD (RZ55)



Antibody

FIG.7F


Binding to amyloid plaques in APP/L



concentration [$\mu\text{g/ml}$]

FIG.7E

Binding to amyloid plaques in AD (RZ16)



concentration [$\mu\text{g/ml}$]

FIG.7G

11/14





FIG.7H

Sandwich-Elisa of Several A β -Forms with Biotinylated Coated Clones

coated anti-A β clone 6G1 ---> A β -Forms ---> biotinylated clone
8C5 ---> Streptavidin-POD ---> development



	A β (1-42) globulomer	A β (1-42) HFIP monomer	A β (1-42) NH ₄ OH monomer	A β (1-40) HFIP monomer	sAPP?
BOTTOM	0.0003317	0.005757	-0.008508	0.0002754	0.0003000
TOP	1.601	1.545	1.137	0.2455	0.06415
LOGEC50	2.755	3.370	4.505	3.794	3.237
HILLSLOPE	1.369	1.377	1.052	0.9842	1.197
EC50	568.2	2346	31991	6222	1725

FIG.8

VH_8C5

GAGGTGCAGTTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGTCCC
TGAAACTCTCCTGTACAGCCTCTGGATTCACTTTCAGTAGCTATGGCATGTCT
TGGGTTCCGCCAGACTCCAGACAAGAGGCTGGAGTTGGTCGCAAGTATTAAAA
ATAATGGTGGTAGCACCTATTATCCAGACAGTTTGAAGGGCCGATTCACCAT
CTCCAGAGACAATGCCAAGAACCCCTGTACCTGCAAATGAGCAGTCTGAAG
TCTGAGGACACAGCCATGTATTATTGTGCAAGTGGGGATTACTGGGGCCAAG
GCACCACTCTCACAGTCTCCTCA (SEQ ID NO:11)

FIG.9A

VL_8C5

GATGTTGTGATGACCCAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCA
AGCCTCCATCTCTTGCAGATCTAGTCAGAGCCTTGTACACAGTAATGGAGAC
ACCTTTTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAGCTCCTGAT
CTACAAAGTTTCCAACCGATTTTCTGGGGTCCAGACAGGTTTCAGTGGCAGTG
GATCAGGGACAGATTTCACTCAAGATCAGCAGAGTGGAGGCTGAGGATCT
GGGAATTTATTTCTGCTCTCAGAGTATACATGTTCCGTGGACGTTTCGGTGGAG
GCACCAAGCTGGAAATCAAACGG (SEQ ID NO:12)

FIG.9B

14/14

VH 8C5

EVQLVESGGGLVQPGGSLKLSCTASGFTFSSYGMSWVRQTPDKRLELVASIKNN
GGSTYYPDLSLKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCASGDYWGQGTT
LTVSS (SEQ ID NO:19)

CDR1 (VH) = SYGMS (SEQ ID NO:13)

CDR2 (VH) = SIKNNGGSTYYPDLSLKG (SEQ ID NO:14)

CDR3 (VH) = SGDY (SEQ ID NO:15)

FIG.10A

VL 8C5

DVVMQTQPLSLPVSLGDAQISCRSSQSLVHSNGDTFLHWYLQKPGQSPKLLIYK
VSNRFSGVPDRFSGSGGTDFTLKISRVEAEDLGIYFCQSQSIHVPWTFGGGTKLEI
KR (SEQ ID NO:20)

CDR1 (VL) = RSSQSLVHSNGDTFLH (SEQ ID NO:16)

CDR2 (VL) = KVSNRFS (SEQ ID NO:17)

CDR3 (VL) = SQSIHVPWT (SEQ ID NO:18)

FIG.10B